Drug Profile
Rilparencel - inRegen
Alternative Names: Autologous cultured kidney tissue cells - inRegen; Autologous cultured kidney tissue cells - Tengion; Autologous Neo-Kidney augment; Neo-Kidney Augment; Neo-kidney-augment; NKA; ReACT; REACT™; Regenerative autologous cell therapy; Renal Autologous Cell TherapyLatest Information Update: 27 Mar 2024
Price :
$50
*
At a glance
- Originator Tengion
- Developer inRegen; ProKidney
- Class Cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Kidney disorders; Type 2 diabetes mellitus
- No development reported Renal failure
Most Recent Events
- 31 Dec 2023 RegenMed completes the phase II trial for Kidney disorders in USA (NCT02836574)
- 13 Nov 2023 ProKidney suspends proact 1 phase III trial in Kidney disorders (associated with Type 2 diabetes mellitus) in USA, Australia, UK, Canada, Taiwan (NCT05099770)
- 13 Nov 2023 Updated interim safety and efficacy data from the phase II trial for Chronic kidney disease released by ProKidney